SecBot SecBot
8-K ·Filed Aug 28, 2026

SPRO

Spero Therapeutics, Inc.
BEARISH
Impact 7/10
Horizonweeks Processed2mo ago SEC0001193125-26-374788
8-K material event: Items 1.01
Actionable Insight ▼ Bearish

The ATM filing signals a distressed capital raise for a pre-revenue biotech. Monitor for SEC effectiveness of the S-3, once effective, the company can begin selling shares into the market, likely pressuring the stock. The prior Cantor facility's zero utilization suggests weak institutional demand; the switch to Jefferies may indicate more aggressive selling terms (3% fee). Short-term traders should watch for any announcement of first drawdown as a negative catalyst.

DirectionBearish
Confidencehigh
Horizonweeks

SP001

◆ Mixed Named in this 8-K
Impact
Phase
Phase 2-ready (Phase 1 completed in healthy volunteers and Sjögren's disease)
Time to market
5+ years (Phase 2 starting Q2 2027; IgG4-RD is an orphan indication but still requires Phase 2 and Phase 3)
Next catalyst
None dated

What to watchSP001 is a new pipeline asset for Spero, announced alongside a $105M non-dilutive royalty financing from Utebzi sales. Watch for the Phase 2 initiation in IgG4-RD (Q2 2027) as the next catalyst. The stock may re-rate on execution towards Phase 2 start, but the $1.1B milestone burden relative to Spero's ~$126M market cap is a significant overhang. Monitor Innovent's Phase 2 SjD data in China (early 2027) as a read-through for the mechanism.

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$1.22
T+0 close · Aug 28, 2026 · via day close
Latest settled
−1.64%
T+20 · $1.20 · next T+60 in 7d
Vs SPY
−1.45%
α at T+20
Latest observation
−10.62%
T+53 · FF3 residual α
  1. T+0 · Aug 31 $1.22entry
  2. T+1 · 3mo ago −1.64%α −0.95% · $1.20
  3. T+5 · 2mo ago −2.46%α −2.32% · $1.19
  4. T+20 · 7w ago −1.64%α −1.45% · $1.20
  5. T+54 · todayOpen
  6. T+60 · in 7d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Spero Therapeutics entered into a new at-the-market (ATM) equity offering agreement with Jefferies LLC for up to $100M in common stock, filed concurrently with a $300M universal shelf registration statement (S-3). The company also terminated its prior $75M Cantor Fitzgerald ATM facility, under which it had sold no shares in FY2025 or FY2024. The new ATM is 1.4x the company's $70M market cap, representing massive potential dilution for a clinical-stage biotech with no approved products or near-term revenue prospects, and the shelf registration was filed just 16 days after a 10-Q showing a $70M market cap, signaling a distressed capital raise to fund preclinical development of SP001.

Key Facts

  • Entered into Open Market Sale Agreement with Jefferies LLC for up to $100M in common stock ATM offering.
  • Filed universal shelf registration statement (S-3) for up to $300M in securities, not yet effective.
  • Terminated prior Cantor Fitzgerald ATM facility ($75M capacity) effective August 28, 2026; no shares sold under that facility in FY2025 or FY2024.
  • The $100M ATM is approximately 1.4x the company's $70M market cap, indicating severe dilution risk.
  • Registration statement is not yet effective; no sales may occur until declared effective by the SEC.

Financial Impact

Potential dilution of up to ~143% of current market cap ($100M ATM vs $70M market cap) if fully utilized; no immediate cash inflow until S-3 declared effective.

dilutionshare countcash balance

Risk Factors

  • Massive dilution risk if the full $100M ATM is utilized relative to a $70M market cap.
  • No approved products or near-term revenue; capital raise funds preclinical SP001 development with uncertain clinical and regulatory outcomes.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (6 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-374788
Document: 0001193125-26-374788-index.html0001193125-26-374788
Document: 0001193125-26-374788.txt0001193125-26-374788

Track record

17 reports on SPRO

Performance horizon

3 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +14.59% at T+20 after the Mar 26, 2026 report. 4 of 7 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Neutral 4/10 Entry $0.9999 Now $0.9460 −5.39% settles Nov 20
  2. Nov 10, 20266d ago 3 Neutral 2/10 Entry $1.02 Now $0.9460 −7.25% settles Nov 18
  3. Nov 10, 20266d ago 8-K Neutral 2/10 Entry $1.02 Now $0.9460 −7.25% settles Nov 18
  4. Oct 27, 202620d ago 8-K Neutral 2/10 Entry $1.17 to $1.07 Now $0.9460 −19.15% ▼ −8.55% −7.83% vs SPY
  5. Sep 11, 20269w ago EFFECT Bearish 7/10 Entry $1.13 to $1.13 Now $0.9460 +16.28% · 0.00% −0.34% vs SPY
  6. Aug 28, 202611w ago 8-K Bearish 7/10 Viewing Entry $1.22 to $1.19 Now $0.9460 +22.46% ▲ +2.46% +2.32% vs SPY
  7. Aug 28, 202611w ago S-3 Bearish 7/10 Entry $1.22 to $1.19 Now $0.9460 +22.46% ▲ +2.46% +2.32% vs SPY
  8. Aug 12, 202613w ago Press Release Neutral 4/10 Entry $1.24 to $1.22 Now $0.9460 −23.71% ▼ −1.61% +0.35% vs SPY
  9. Jul 14, 202617w ago 8-K Bullish 8/10 Entry $1.70 to $1.44 Now $0.9460 −44.35% ▼ −15.29% −14.00% vs SPY
  10. Jul 14, 202617w ago Press Release Bullish 7/10 Entry $1.70 to $1.44 Now $0.9460 −44.35% ▼ −15.29% −14.00% vs SPY
Showing 10 of 17

US Market Status

Market Closed · Opens Wed (10h 26m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 28, 2026